Customisable Bioink Technology Platform
One of 10,000+ projects Taiyo tracks in United Kingdom.
Source: EU Funding & Tenders Portal
3D cell culture and 3D Bioprinting have become crucial to the development of health and life science research. 3D cell culture has enabled more accurate cell screening, drug and biosensor discovery, tissue engineering, and development of cell lines. One of the major challenges to culturing complex tissues is producing detailed matrix morphologies with optimised pore size, mechanical properties and
- Status
- Closed
- Sector
- Chemical (Industrial), Manufacturing (Industrial)
- Location
- United Kingdom
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Customisable Bioink Technology Platform
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | 3D cell culture and 3D Bioprinting have become crucial to the development of health and life science research. 3D cell culture has enabled more accurate cell screening, drug and biosensor discovery, tissue engineering, and development of cell lines. One of the major challenges to culturing complex tissues is producing detailed matrix morphologies with optimised pore size, mechanical properties and biocompatibility. Many of the bioink 3D matrices under development do not sufficiently address the physical (mechanical properties), chemical and biological (cell-matrix interactions) complexity required for sucessful 3D culture. PGD have developed an eight amino acid sequence peptide that self-assembles and forms a hydrogel in the presence of a salt solution. This platform technology is commerically available for 3D culture or tissue engineering research and can be purchased as a liquid or spray. PGD are now investigating the feasibility of producing a bioink. PGD will produce a bioink and disposable mixing chamber that can be 3D printed and support cell viability. For additive manufacturing to break through in the life sciences and pharma industry, a complete package must be provided, including ready to use inks that are true 3D ECM mimics and compatible with processing methods. They must not impede staining/assays or optical/electrochemical detection of cells. At present, there is no bioink on the market that is suitable for large scale use in the pharmaceutical and life science industries. |
Location
Country | United Kingdom (UK) |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Chemical (Industrial), Manufacturing (Industrial) |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Chemical (Industrial) projects in United Kingdom
- Coryton Refinery
- Rodda’s Clotted Cream Filling Machine Upgrade
- Phoenix Chemicals Manufacturing Facility
- Sai Life Sciences’ Process Chemistry R&D Laboratory Expansion, Manchester
- Novartis’ API Plant in Grimsby, West Yorkshire, UK
- Saltend Bioethanol Plant, Hull
- Heinz Canning Plant Energy Efficiency Expansion
- Rachel’s Organic Dairy, Aberystwyth
